- Home
- GILD vs GOOGM Comparison
GILD vs GOOGM Comparison
Compare GILD & GOOGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
GOOGM
Alphabet Inc. Depositary Shares representing a 1/20th Interest in a Share of Series A Mandatory Convertible Preferred Stock
Current Price
Company Overview
Basic Information| Metric | GILD | GOOGM |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0B | 624.3B |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GILD | GOOGM |
|---|---|---|
| Price | $135.71 | $48.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 18 | 0 |
| Target Price | ★ $148.39 | N/A |
| AVG Volume (30 Days) | ★ 6.5M | 1.2M |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 1684.21 | 34.45 |
| EPS | N/A | ★ 14.24 |
| Revenue | $24,689,000,000.00 | ★ $402,836,000,000.00 |
| Revenue This Year | $4.68 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | ★ N/A | $3.45 |
| Revenue Growth | 9.98 | ★ 15.09 |
| 52 Week Low | $108.46 | $46.24 |
| 52 Week High | $157.29 | $53.13 |
Technical Indicators
Market Signals| Indicator | GILD | GOOGM |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 46.90 |
| Support Level | $128.15 | $48.45 |
| Resistance Level | $138.40 | $52.44 |
| Average True Range (ATR) | 3.70 | 1.08 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 56.41 | 40.57 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).